Cell-ing the Future: CytoImmune’s CEO Talks About Expanded Role in Cell Therapy

  Dr. Jose E Vidal who is currently the CEO of CytoImmune Therapeutics, a company at the forefront of a novel natural killer cell therapy for lung cancer, currently in phase 1 clinical trials joins eHealth Radio and the <a href="https://ehealthradio.podbean.com/category/health-news" target="_blank" rel="noreferrer noopener">Health News</a> and <a href="https://ehealthradio.podbean.com/category/cancer-information" target="_blank" rel="noreferrer noopener">Cancer Information</a> Channels. Listen to interview with host <a href="https://www.linkedin.com/in/ericmdye/" target="_blank" rel="noreferrer noopener">Eric Michaels</a> and guest Dr. Jose E. Vidal discuss the following: <ol><li>What is gene and cell therapy and how does it work?</li><li>What conditions can be treated with cell therapy?</li><li>What is the difference between treatment therapy and curative therapy?</li><li>What is the difference between chemo/radio therapy and immunotherapy for cancer?</li><li>When will cell therapy be available to patients? What are the limitations?</li></ol>In conclusion, cell therapy is the next significant step in fighting hard to treat cancer and autoimmune conditions. It has been proven to provide results superior to any treatment seen before. Now, we are working on improving access for patients by optimizing the manufacturing process and lowering therapy cost. Dr. Jose Eduardo Vidal obtained his doctoral degree in Cellular and Molecular Biology from the University of Puerto Rico. He started his career in the pharmaceutical industry in Wyeth as a process development scientist working with small molecules and the first Biologics development pipeline upon the acquisition of Immunex. With Wyeth he worked on the development and commercial launch of Mylotarg (very first ADC). He continued to develop as a biopharmaceutical professional occupying positions of increased responsibility in Tech Services, Process Development and Quality. After 10 years with the company and managing 14 sites world wide Jose joined Amgen as the head